The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice
Open accessAbstract
Glucagon, the counter-regulatory hormone to insulin, is secreted from pancreatic α cells in response to low blood glucose. To examine the role of glucagon in glucose homeostasis, mice were generated with a null mutation of the glucagon receptor (Gcgr −/− ). These mice display lower blood glucose levels throughout the day and improved glucose tolerance but similar insulin levels compared with control animals. Gcgr −/− mice displayed supraphysiological glucagon levels associated with postnatal enlargement of the pancreas and hyperplasia of islets due predominantly to α cell, and to a lesser extent, δ cell proliferation. In addition, increased proglucagon expression and processing resulted in increased pancreatic glucogen-like peptide 1 (GLP-1) (1–37) and GLP-1 amide (1–36 amide) content and a 3- to 10-fold increase in circulating GLP-1 amide. Gcgr −/− mice also displayed reduced adiposity and leptin levels but normal body weight, food intake, and energy expenditure. These data indicate that glucagon is essential for maintenance of normal glycemia and postnatal regulation of islet and α and δ cell numbers. Furthermore, the lean phenotype of Gcgr −/− mice suggests glucagon action may be involved in the regulation of whole body composition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nonetheless, continuous infusion of GLP-164, or repeated administration of DPP-4 inhibitors65, improve glucose metabolism in subjects with T2D.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [64]
In the citing paper
“Analyses from ACCORD suggest that the individual likely to be at greatest risk of an adverse outcome to aggressive glucose lowering had a longer duration of diabetes, poor glucose control at the time of commencing intensive insulin therapy, and did not demonstrate an immediate glucose lowering response125.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [125]
Citations
Cites
Handbook of Experimental Pharmacology.
Meakin, J. W. (1971) · Archives of Internal Medicine · doi:10.1001/archinte.1971.00310230151026 · Cited by 1,959
Kieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
A Molecular Basis for Insulin Resistance
Paz, K., Hemi, R., LeRoith, D., Karasik, A., Elhanany, E., Kanety, H., & Zick, Y. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.47.29911 · Cited by 549
The Pancreas : biology, pathobiology, and disease
Go, V. L. W. (1993) · Raven Press eBooks · Cited by 526
Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4
Katz, E. B., Stenbit, A. E., Hatton, K., DePinhot, R., & Charron, M. J. (1995) · Nature · doi:10.1038/377151a0 · Cited by 471
Self-citationProteolytic Processing in the Secretory Pathway
Zhou, A., Webb, G., Zhu, X., & Steiner, D. F. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.30.20745 · Cited by 457
Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2
Furuta, M., Yano, H., Zhou, A., Rouillé, Y., Holst, J. J., Carroll, R., Ravazzola, M., Orci, L., Furuta, H., & Steiner, D. F. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6646 · Cited by 431
Self-citationMinireview: The Glucagon-Like Peptides
Drucker, D. J. (2001) · Endocrinology · doi:10.1210/en.142.2.521 · Cited by 421
Expression cloning and signaling properties of the rat glucagon receptor
Jelinek, L., Lok, S., Rosenberg, G., Smith, R., Grant, F., Biggs, S., Bensch, P., Kuijper, J., Sheppard, P., Sprecher, C., et al. (1993) · Science · doi:10.1126/science.8384375 · Cited by 397
Recent Advances in Our Understanding of Insulin Action and Insulin Resistance
Le Roith, D., & Zick, Y. (2001) · Diabetes Care · doi:10.2337/diacare.24.3.588 · Cited by 337
Research works printed but not linked: 3
- R Burcelin, E B Katz, M J Charron Diabetes Metab 22, 373–396 (1996).
- 10.1210/endo.142.2.7983 · doi:10.1210/endo.142.2.7983 · Paper page
- D T Stein, E E Babcock, C R Malloy, J D McGarry Int J Obes Relat Metab Disord 19, 804–810 (1995).
Cited by
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Self-citationEnergy Metabolism in the Liver
Rui, L. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130024 · Cited by 1,953
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Metformin—mode of action and clinical implications for diabetes and cancer
Pernicova, I., & Korbonits, M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.256 · Cited by 1,349
Metadata
- Authors
- Gelling, R. W., Du, X. Q., Dichmann, D. S., Rømer, J., Huang, H., Cui, L., Obici, S., Tang, B., Holst, J. J., Fledelius, C., Johansen, P. B., Rossetti, L., Jelicks, L. A., Serup, P., Nishimura, E., & Charron, M. J.
- Affiliations
- Albert Einstein College of Medicine (US)
- Corresponding author
- Charron, M. J.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2003-01-24
- Volume
- 100
- Issue
- 3
- Pages
- 1438-1443
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC298791
- OpenAlex
- W2127167047
- Cited by
- 563
- References
- 42
- Citations by year
- 2026: 17 · 2025: 17 · 2024: 28 · 2023: 30 · 2022: 31 · 2021: 27 · 2020: 26 · 2019: 28 · 2018: 23 · 2017: 26 · 2016: 23 · 2015: 45 · 2014: 31 · 2013: 39 · 2012: 28
- FWCI
- 12.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- American Diabetes Association
- Sundhed og Sygdom, Det Frie Forskningsråd
- National Institutes of Health
- Albert Einstein College of Medicine, Yeshiva University
- Medical Research Council
- National Heart, Lung, and Blood Institute (HL-58119, R01HL058119)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK047425, DK-47425)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- glucagon, glucagon receptor, hyperglucagonemia, proglucagon processing, glucagon-like peptide-1, glucose homeostasis, hypoglycemia, glucose tolerance, islet hyperplasia, adiposity, leptin, body composition
- MeSH terms
- Cyclic AMP, Animals, Blood Glucose, Body Weight, Calorimetry, Cell Division, Epididymis, Epinephrine, Glucagon, Glucose, Hormones, Hyperplasia, Immunohistochemistry, Insulin, Islets of Langerhans, Liver, Male, Mice, Inbred C57BL, Microscopy, Fluorescence, Phenotype, Time Factors, Receptors, Glucagon, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice. https://app.cochat.ai/papers/10.1073/pnas.0237106100
- The paper
- Gelling, R. W., Du, X. Q., Dichmann, D. S., Rømer, J., Huang, H., Cui, L., Obici, S., Tang, B., Holst, J. J., Fledelius, C., Johansen, P. B., Rossetti, L., Jelicks, L. A., Serup, P., Nishimura, E., & Charron, M. J. (2003). Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0237106100
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.